INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Stuttgart
03.03.26 | 17:03
1,370 Euro
-2,84 % -0,040
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,370 | 1,420 | 18:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 | 275 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 18.02. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.02. | Innate Pharma SA: Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference | 263 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 07.01. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 07.01. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | 428 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 22.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 | 382 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 11.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.12.25 | Innate Pharma SA: Innate Pharma Releases Its 2026 Financial Calendar | 647 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial... ► Artikel lesen | |
| 28.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.11.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 | 587 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 17.11.25 | Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference | 377 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of... ► Artikel lesen | |
| 13.11.25 | Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances | 1 | Investing.com | ||
| 13.11.25 | Innate Pharma reports 9M results | 1 | Seeking Alpha | ||
| 13.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11.25 | Innate Pharma SA: Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | 440 | Business Wire | Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502... ► Artikel lesen | |
| 10.11.25 | Innate Pharma: Aktie legt nach grünem Licht der FDA für Phase-3-Studie kräftig zu | 13 | Investing.com Deutsch | ||
| 10.11.25 | Innate Pharma SA: Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL | 464 | Business Wire | The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line... ► Artikel lesen | |
| 05.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11.25 | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | 338 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at... ► Artikel lesen |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,382 | -1,43 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| XOMA ROYALTY | 22,200 | -1,77 % | XOMA Royalty Corp - 8-K, Current Report | ||
| TME PHARMA | 0,061 | -11,30 % | TME Pharma NV: TME Pharma provides update on its activities | TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| CANSINO BIOLOGICS | 3,472 | -3,50 % | CanSino Biologics Inc: CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential | HONG KONG, Feb 24, 2026 - (ACN Newswire) - CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by... ► Artikel lesen | |
| KARYOPHARM | 7,950 | -3,64 % | Karyopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress | - Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 -
- Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,322 | -4,73 % | XFRA MAH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,900 | +0,72 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY (sebetralstat) | Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials
KalVista Pharmaceuticals... ► Artikel lesen | |
| ADICET BIO | 5,950 | -4,03 % | XFRA 1IJ: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ANNOVIS BIO | 2,225 | -2,84 % | Annovis Bio Inc.: Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease | MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 8,800 | -7,85 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance | PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,260 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 80,00 | -1,84 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity | -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,246 | -27,65 % | RECCE PHARMACEUTICALS LTD: Appendix 4D and Interim Financial Report | ||
| QIAGEN | 40,700 | -1,44 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften |
Das Unternehmen INNATE PHARMA SA ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,370 Euro und damit -2,84 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.